1. China Stocks

  2. •

    Health technology

  3. •

    Biotechnology
Beijing SL Pharmaceutical Co. Ltd. Class A

Beijing SL Pharmaceutical Co. Ltd. Class A

SSZSE:002038
5.27
CNY
+0.16
(+3.13%)
-0.43EPS
7.80BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.13
1.21
1.13
0.98
1.21
3.16
1.96
1.1
1.17
1.03
1
0.62
0.61
0.57
Basic EPS, GAAP
0.56
0.68
0.56
0.44
0.52
0.83
0.47
0.36
0.41
0.23
0.41
-0.07
-0.34
-0.42
Free Cash Flow per Basic Share
0.23
0.31
0.37
0.23
0.15
0.38
0.38
0.16
0.22
0.22
0.24
-0.12
0.06
- -
Dividend per Share
0.09
0.09
0.13
0.13
0.13
0.5
0.2
0.2
0.1
0.1
0.1
0.15
0.02
- -
Book Value per Share
2.5
3.06
3.48
3.79
4.16
4.4
4.68
4.84
5.17
5.32
5.65
5.42
5.04
4.96
Tangible Book Value per Share
2.32
2.87
3.27
3.54
3.8
3.71
4.06
4.15
4.32
4.37
4.53
4.26
3.94
3.87
Basic Weighted Avg Shares
1,031
1,027
1,027
1,027
1,027
685
1,036
1,013
1,039
1,019
1,016
1,058
1,021
1,070
Sales/Revenue/Turnover
1,162
1,243
1,157
1,010
1,242
2,167
2,030
1,113
1,215
1,050
1,018
660
624
607
Operating Margin (%)
52.32
58.2
49.87
45.79
31.15
30.87
24.82
15.22
21
17.33
24.56
6.63
-0.42
5.11
Depreciation Expense
23
31
33
34
37
56
77
89
100
114
145
153
167
- -
Net Income, GAAP
577
695
575
452
534
571
487
365
426
234
417
-74
-347
-453
Effective Tax Rate (%)
15.09
13.71
13.69
15.17
15.08
16.12
14.51
12.43
7.97
11.96
10.74
- -
- -
- -
Profit Margin (%)
49.7
55.92
49.72
44.77
42.96
26.36
23.98
32.78
35.06
22.32
40.92
-11.21
-55.67
-74.74
Working Capital
1,622
2,167
2,473
2,624
2,803
2,363
2,533
1,892
1,973
1,709
2,267
2,199
1,364
1,444
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
2
- -
- -
- -
- -
- -
Total Equity
2,589
3,181
3,613
3,930
4,299
4,543
4,821
4,985
5,326
5,479
5,810
5,581
5,189
5,101
Return on Invested Capital (%)
23.33
23.1
16.57
11.36
12.77
12.89
10.27
7.43
8.27
4.37
7.73
- -
- -
- -
Return on Capital (%)
24.8
23.89
16.37
11.71
12.71
12.71
10.55
7.5
8.35
4.45
7.41
- -
- -
- -
Return on Common Equity (%)
25.07
24.33
17.1
12.1
13.07
13
10.43
7.46
8.28
4.35
7.4
-1.3
-6.46
-8.5

Capital Structure

CNY

•

in mil. unless spec.
Jun'25
Dec'25
Mar'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,027
1,027
1,027
Market Capitalization
7,284
7,572
7,798

Working Capital

CNY

•

in mil. unless spec.
Jun'25
Dec'25
Mar'26
Total Current Assets
2,563
2,094
2,049
Cash, Cash Equivalents & STI
887
1,018
1,156
Accounts Receivable, Net
86
81
83
Inventories
415
682
555
Total Current Liabilities
200
730
605
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
3.81%
0.96%
-7.03%
Free Cash Flow
-26.56%
-50.96%
-153.07%
Net Income, GAAP
26.44%
60.12%
368.77%
Sales/Revenue/Turnover
-1.49%
-9.63%
-5.57%
Total Cash Common Dividend
- -
- -
-88.39%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
245
147
148
120
660
2025
169
136
- -
165
624
2026
137
- -
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.07
-0.04
-0.05
-0.06
-0.07
2025
0.04
0.07
- -
-0.48
-0.34
2026
-0.08
- -
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.15
2025
- -
- -
- -
- -
0.02
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Ming Bo Xu
Full Time Employees
901
Sector
Health technology
Industry
Biotechnology
Address
Building 1, Bitongyuan Beijing BE China 100143
IPO Date
Sep 9, 2004
Website
slpharm.com.cn
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
Beijing SL Pharmaceutical Co., Ltd. (002038.SZ) develops, manufactures, and markets genetic engineering drugs, biological products, biochemical drugs, chemical preparations, and related pharmaceuticals primarily for hematology, oncology, immunology, cardiovascular, anti-infective, diabetes, digestive, neurological, musculoskeletal, anti-allergic, urinary, and peptide hormone therapeutic areas. Core products include recombinant human granulocyte colony-stimulating factor (rhG-CSF) injections; interleukin-2 (rhIL-2), interleukin-11 (rhIL-11), and basic fibroblast growth factor (rh-bFGF) injections; biochemicals such as cytidine disodium triphosphate, calcium folinate, salmon calcitonin, coenzyme complex, netilmicin sulfate, matrine, and cyclosporin injections; chemical drugs encompassing tablets and capsules like desloratadine orally-disintegrating tablets, zaleplon capsules, naftopidil tablets, tropisetron hydrochloride capsules, telmisartan tablets, metformin hydrochloride/glyburide tablets, stavudine capsules, temozolomide, paclitaxel, gemcitabine, asparaginase; and dosage forms such as small-volume injections, freeze-dried powder injections, granules, hard capsules, soft gels, nasal preparations, oral liquids, aerosols, sprays, and health-care foods including Hongxin Capsule. The company operates production facilities and sales networks across China, with offices in Beijing, Liaoning, and Henan provinces, targeting domestic markets and select overseas distribution. Founded in 1994 and headquartered at 4th Floor, Building 1, Bitongyuan, No. 69 Fushi Road, Haidian District, Beijing, China, it maintains approximately 889 employees and holds 61 patents, including three national-level new drugs with independent intellectual property rights. In recent developments as of November 2025, the company advances a GLP-1 long-acting product toward regulatory submission by compiling necessary documentation, reflecting strategic expansion into metabolic therapies amid China's innovative drug boom.